Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert E Widdop

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Hypertension (Dallas, Tex. : 1979)|August 20, 2008
Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female ratsAmanda K Sampson, Karen M Moritz, Emma S Jones, et al.
Hypertension (Dallas, Tex. : 1979)|November 30, 2011
Sex differences in the pressor and tubuloglomerular feedback response to angiotensin IIRussell D Brown, Lucinda M Hilliard, Geoffrey A Head, et al.
Plos One|April 23, 2014
Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive ratsClaudia A McCarthy, Antony Vinh, Alyson A Miller, et al.
Hypertension (Dallas, Tex. : 1979)|June 18, 2014
Role of inflammation and the angiotensin type 2 receptor in the regulation of arterial pressure during pregnancy in miceKatrina M Mirabito, Lucinda M Hilliard, Zihui Wei, et al.
Hypertension (Dallas, Tex. : 1979)|October 24, 2012
Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious ratsClaudia A McCarthy, Antony Vinh, Brad R S Broughton, et al.
Frontiers in Pharmacology|February 18, 2015
Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2Daniel Clayton, Iresha Hanchapola, Walter G Thomas, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 4, 2021
Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive miceYifang Li, Amlan Chakraborty, Brad R S Broughton, et al.
Life Sciences|May 23, 2026
Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart diseaseZiqiao Wang, Gang She, Chao Wang, et al.
Clinical Science (London, England : 1979)|July 1, 2025
The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosisSimon G Royce, Cem Erdem, WeiYi Mao, et al.
Clinical Science (London, England : 1979)|January 19, 2026
Sex-dependent differences in the progression of renal injury and fibrosis following ischemic acute kidney injurySharon D Ricardo, Tingfang Zhang, Zoe McArdle, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Hypertension (Dallas, Tex. : 1979)|August 20, 2008
Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female ratsAmanda K Sampson, Karen M Moritz, Emma S Jones, et al.
Hypertension (Dallas, Tex. : 1979)|November 30, 2011
Sex differences in the pressor and tubuloglomerular feedback response to angiotensin IIRussell D Brown, Lucinda M Hilliard, Geoffrey A Head, et al.
Plos One|April 23, 2014
Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive ratsClaudia A McCarthy, Antony Vinh, Alyson A Miller, et al.
Hypertension (Dallas, Tex. : 1979)|June 18, 2014
Role of inflammation and the angiotensin type 2 receptor in the regulation of arterial pressure during pregnancy in miceKatrina M Mirabito, Lucinda M Hilliard, Zihui Wei, et al.
Hypertension (Dallas, Tex. : 1979)|October 24, 2012
Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious ratsClaudia A McCarthy, Antony Vinh, Brad R S Broughton, et al.
Frontiers in Pharmacology|February 18, 2015
Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2Daniel Clayton, Iresha Hanchapola, Walter G Thomas, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 4, 2021
Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive miceYifang Li, Amlan Chakraborty, Brad R S Broughton, et al.
Life Sciences|May 23, 2026
Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart diseaseZiqiao Wang, Gang She, Chao Wang, et al.
Clinical Science (London, England : 1979)|July 1, 2025
The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosisSimon G Royce, Cem Erdem, WeiYi Mao, et al.
Clinical Science (London, England : 1979)|January 19, 2026
Sex-dependent differences in the progression of renal injury and fibrosis following ischemic acute kidney injurySharon D Ricardo, Tingfang Zhang, Zoe McArdle, et al.
Pageof 12